DMT for Health & Longevity - Quick Reference Sheet

DMT for Health & Longevity

Created on 08/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A fast-acting compound found in plants and in trace amounts in the body; injected or inhaled, the experience is over within about twenty minutes. Strongest evidence: rapid, sometimes months-long reduction in depression severity after one supervised dose. Serious harms concentrate in people with a personal or family history of psychosis or mania. (Full Review)

Protocol

Intravenous infusion — the pharmaceutical standard
21.5 mg over 10 minutes
DMT fumarate with psychotherapeutic support; plateau of 20–30 minutes.
Vaporized or inhaled — the emerging clinical route
15 mg then 60 mg
Temperature-controlled vaporizer; avoids venous access.
Single dose versus split or repeated dosing
One or two single doses
Single rather than divided dosing; one and two doses did not differ.
Time to effect
Depressive symptoms
Within 24 hours
Typically measured at 1 and 2 weeks; persisted to 3 months.
Mindfulness and self-compassion
One day post-dose
After a DMT-plus-harmine formulation; durability not established.
Quality of life and life satisfaction
Sustained to 12 months
12 months in patients, 14 days in healthy volunteers; open-label.

Benefits

Contraindications
  • Personal or first-degree family history of schizophrenia, schizoaffective disorder, or bipolar I disorder; current psychotic symptoms
  • Uncontrolled hypertension (above 140/90 mmHg)
  • Recent myocardial infarction (within 90 days), unstable angina, or NYHA Class III–IV heart failure
  • Valvular disease or aortic aneurysm; QTc >500 ms
  • History of stroke or intracranial haemorrhage
  • Poorly controlled epilepsy
  • Pregnancy and breastfeeding
  • Child-Pugh Class B or C hepatic impairment
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, linezolid)
Key Interactions
  • Selective serotonin and serotonin-norepinephrine reuptake inhibitors (sertraline, venlafaxine)
  • Tricyclic antidepressants and lithium (amitriptyline, clomipramine)
  • Over-the-counter medications (dextromethorphan, chlorpheniramine, pseudoephedrine)
  • Serotonergic or monoamine oxidase-inhibiting supplements (St. John's wort, 5-HTP, Syrian rue)
  • Supplements with cardiovascular effects (yohimbine, synephrine, high-dose caffeine)
  • Other psychedelics and dissociatives (psilocybin, LSD, ketamine)
  • Cannabis

Risk & Side Effects

  • High: Acute cardiovascular stimulation; intense and potentially distressing acute psychological effects
  • Medium: Nausea and vomiting; serotonin toxicity with monoamine oxidase inhibitors or serotonergic medications; transient anxiety, headache, and fatigue
  • Low: Acute psychosis or mania; hallucinogen persisting perception disorder; local irritation; tinnitus
  • Speculative: Valvular heart disease with frequent use; reproductive and developmental harm; psychiatric destabilization

Monitoring

Marker Target Why
Blood pressure (seated, rested) 110–120 / 70–78 mmHg Headroom for the pressor response
Resting heart rate 50–70 bpm Baseline for the acute tachycardia
Electrocardiogram, QTc interval <440 ms (male), <450 ms (female) Screens for arrhythmia risk
Comprehensive metabolic panel ALT and AST 10–26 U/L; creatinine 0.7–1.1 mg/dL Hepatic and renal clearance
Complete blood count Haemoglobin 13.5–15.0 g/dL (male), 12.5–14.5 g/dL (female) Anaemia or occult illness
Thyroid-stimulating hormone 0.5–2.0 mIU/L Mimics depression and anxiety
High-sensitivity C-reactive protein <0.5 mg/L Baseline inflammatory tone
Morning cortisol 10–18 µg/dL at 8 a.m. Session acutely raises cortisol
Fasting glucose and HbA1c Glucose 75–86 mg/dL; HbA1c 4.8–5.2% Metabolic health screen

Cadence: Continuous vital signs during and for 60–90 minutes after the session; symptom and blood-pressure review at 24 hours, 1 week, and 4 weeks; laboratory review at 3 months, then every 6–12 months.

Qualitative Assessment

  • Mood and anhedonia: whether previously enjoyable activities are again engaging
  • Sleep quality: time to fall asleep, night-time awakenings, and morning refreshment
  • Anxiety and rumination: frequency and duration of repetitive negative self-focused thought
  • Cognitive clarity: subjective attention, word-finding, and task-switching capacity
  • Social engagement and relationship quality: sustained at 12-month follow-up
  • Sense of meaning and forward orientation: plans and hope rather than endurance
  • Integration quality: concrete behavioural change by 4 weeks